Search

Displaying results 3791 - 3800 of 9710 in total
  1. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by _ERBB2_ overexpression, a higher grade, a more aggressive phenotype, and a worse prognosis compared to HER2-negative … The HER2 oncoprotein, the product of the human _ERBB2_/mouse _neu_ genes, is a member of the HER family of receptor tyrosine kinases that includes the epidermal growth factor receptor (EGFR).

  2. Drug

    Alobresib

    go.drugbank.com/drugs/DB14970
    Investigational

    Alobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants

  3. Drug

    Padsevonil

    go.drugbank.com/drugs/DB14977
    Investigational

    Padsevonil is under investigation in clinical trial NCT03695094 (A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil).

  4. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    with a possible increased risk of death outweighing the benefits. … Unfortunately, many patients experience a relapse or develop resistance to these drugs.

  5. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    Brepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. It inhibits TYK2- and JAK1-mediated cytokine signaling, blocking phosphorylation of signal transducers and activat...

  6. Drug

    Viltolarsen

    go.drugbank.com/drugs/DB15005
    ApprovedInvestigational

    links between nucleotides are replaced with a phosphorodiamidate linkage. … A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by the production of shortened and partially functional dystrophin protein.

  7. Drug

    Palladium Pd-103

    go.drugbank.com/drugs/DB15016
    Experimental

    Palladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).

  8. Drug

    Apomab

    go.drugbank.com/drugs/DB15022
    Investigational

    Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced

  9. Drug

    Adriforant

    go.drugbank.com/drugs/DB15027
    Investigational

    Adriforant is under investigation in clinical trial NCT00992342 (A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers).

  10. Drug

    Tavolixizumab

    go.drugbank.com/drugs/DB15042
    Investigational

    Tavolixizumab is under investigation in clinical trial NCT02318394 (A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors).